I have not posted for a while, Had enough of some of the posters on this board, No need to mention names.
My question is I feel a little uneasy. The Company's news release did not really give any concrete facts, IMO for the stock to have rallied so high. Again my thought only.
Below is part of what has been posted
The mid-stage study, which evaluated results of 172 patients, compared with the previously reported analysis of 114 patients, showed good tolerability and (((( meaningful improvement)))) in overall survival in patients with non-small cell lung cancer.
(((( "If confirmed )))) on final maturity, this overall survival benefit would be highly robust," Jefferies analyst Thomas Wei wrote in a client note.
I have placed parenthesis around my unease.
You all know I believe in SNTA and want nothing more for this stock to go to $50. Anyone taking some of the table, or are you just holding for the next NEWS.
Am I missing something. Maybe I should be buying more. Looking for advice from the Longs.
That is the language you will hear upon interim data analysis in a small phase II trial. Nothing wrong with taking some profit. As I stated, I may join you soon, and will certainly do so as the final phase II trial data approaches and is presented for reasons I previously explained.
If you also notice, tech_trader hasn't been honest with anyone by simply acknowledging his absurd comments about Ganetespib getting FDA approved in 6 months, BEFORE there was even a shred of data from the phase II trial. If you notice, the simpleton trolls now hurl out the names PPHM and ARQL as if they are imposing some wisdom relevant to every stock the moment it rises.
Nice to see all of you guys back. I recently re-entered snta in a small position with about a 25% gain....nothing compared to you guys that probably got close to a 100% gain. Anyways, the only thing I could think of a positive was that even though results were not excellent but it was that results were moving in a positive direction. It's good to take profits but at the same time I believe that synta got positive publicity with analyst upgrades, raised price targets, analyst initiations with a buy, and relatively defined catalyst dates. Synta may also attract biorunup traders. I purchased the wallstreet transcript about a week ago and posted that information on synta on my last post if you guys want to take a look at it. Post getting too long.